First International Gliomatosis cerebri (GC) group meeting. March 26–27, 2015. Paris, France

**Thursday March 26**

10:30 am – 11:00 am  
Registration

11:00 am – 11:15 am  
**Welcoming: Andres Morales**  
*Foundations and Families*

11:15 am – 12:30 pm  
**Introductory session: Jeffrey P. Greenfield**

11:15 am – 11:45 am  
Title: TBD

11:45 am – 12:30 pm  
Open discussion:

- What is the definition of GC?
- What are the signs and symptoms?
- What are the radiologic diagnostic criteria?
- What are the histologic diagnostic criteria?
- How should we establish the diagnosis?
- How relevant is obtaining tissue sampling at diagnosis?
- How relevant is obtaining tissue sampling at progression?
- Is there a “standard of care” for patients with GC?

12:30 pm – 2:30 pm  
**GC basic science session: Luis F. Parada**

12:30 pm – 1:15 pm  
Title: TBD

1:15 pm – 2:30 pm  
Open discussion:

- What regulates normal astrocyte migration and invasion in brain development?
What are the initiating events for gliomagenesis and which are the main pathways implicated?

Have we identified the glioma stem cell yet (and it is the same for GC as for GBM)?

What are the current/potential biologic pathways of interest?

What are the experiments of interest?

What is the role of the brain cellular context for the initiation and maintenance of GC?

2:30 pm – 3:00 pm

Lunch break

3:00 pm – 6:00 pm

Translational biology in GC: Mark W. Kieran

3:00 pm – 3:45 pm

Title: Applicability of DIPG/pHGG translational research approaches to GC research strategy

3:45 pm - 6:00 pm

Open discussion:

- What are the steps we need to follow in order to uncover the genetic, epigenetic and translational events necessary for the development of GC and other invasive gliomas?
- What molecular markers could we propose to define better this entity?
- Are there any established cell lines that we could or should support?
- Are there any animal models we could use as a model to follow in GC?
- What is the list of drugs we should be considering for testing in the preclinical/clinical setting?

8 pm

Dinner
Friday March 27

8:30 am – 9:30 am
The role of tissue sampling in GC: Jeffrey P. Greenfield

8:30 am – 9:00 am
Title: TBD

9:00 am – 9:30 am
Open discussion:
- What should be the optimal surgical approach for obtaining diagnostic material in patients with suspected GC?
- What are the minimal requirements for the tissue obtained?
- Should we centralize the samples for analysis?

9:30 am – 11:30 am
Therapeutic implications in GC: David T.W. Jones and Chris Jones

9:30 am – 10:30 am
Title: TBD

10:30 am – 11:30 am
Open discussion:
- Is there consensus in the diagnosis and treatment of GC?
- Is GC more than one disease?
- Is there a difference between pediatric and adult GC?
- Is there a difference between patients diagnosed with primary GC vs 2nd development?
- What can we learn from that?
- Is there any difference based on what area of the CNS is involved?
- Is there anything we can learn/apply from other infiltrative gliomas research discoveries (i.e. DIPG/GBM)?
- What makes GC and other infiltrative glial tumors so resistant to current therapies?
- How do these tumors acquire treatment resistance?

-----------------------------------------------------------------------------------
11:30 am - 1:00 pm
Therapeutic implications in GC, the adults’ experience: Patrick Y. Wen

11:30 am – 12:15 pm
Title: Therapeutic implications in GC, the adults’ experience

12:15 – 1:00 pm
Open discussion:
- Is there consensus in the diagnosis and treatment of GC in the adult population?
- What are the treatment recommendations?
- Is GC more than one disease?
- Is there a difference between patients diagnosed with primary GC vs 2nd development?
- How drugs like bevacizumab can change the tumor phenotype?
- What can we learn from that?
- Is there any difference based on what area of the CNS is involved?
- Is there anything we can learn/apply from other infiltrative gliomas research discoveries (i.e. GBM)?
- What makes GC and other infiltrative glial tumors so resistant to current therapies? How do these tumors acquire treatment resistance?

------------------------------------------------------------------------------

1:00 pm – 1:45 pm
Lunch break

------------------------------------------------------------------------------

1:45 pm – 2:30 pm
Working towards a GC international registry: Jeffrey P. Greenfield

1:45 pm – 2:05 pm
Title: TBD

2:05 – 2:30 pm
Open discussion:
- Would different groups support a common/shared prospective international registry?
- What can we learn from other international registries for rare diseases?
- What is the best strategy in order to collect existing samples and epidemiologic data?
- How are we going to share our data?
- How would we share data and samples in different collaborative projects?
2:30 pm – 3:30 pm
**Next Steps: Andres Morales**
Joined meeting for foundations and researchers to line out the roadmap for relevant future projects and next meeting

3:30 pm – 4:30 pm
**Fundraising and the Foundations: Speaker TBD**

- How to support international collaborative fundraising strategies?
- Should we aim for one international foundation that leads the fundraising initiatives and directs the funds collected?
- How to access funding for projects?
- What can we do to help?

**Addendum**
Families and foundations will hold a meeting in a separate room with the goal of finding ways to collaborate in fund raising initiatives.